全文获取类型
收费全文 | 7015篇 |
免费 | 507篇 |
国内免费 | 57篇 |
专业分类
耳鼻咽喉 | 81篇 |
儿科学 | 189篇 |
妇产科学 | 106篇 |
基础医学 | 997篇 |
口腔科学 | 187篇 |
临床医学 | 714篇 |
内科学 | 1632篇 |
皮肤病学 | 100篇 |
神经病学 | 652篇 |
特种医学 | 373篇 |
外科学 | 1047篇 |
综合类 | 72篇 |
一般理论 | 5篇 |
预防医学 | 377篇 |
眼科学 | 130篇 |
药学 | 366篇 |
中国医学 | 8篇 |
肿瘤学 | 543篇 |
出版年
2023年 | 51篇 |
2022年 | 42篇 |
2021年 | 150篇 |
2020年 | 135篇 |
2019年 | 170篇 |
2018年 | 206篇 |
2017年 | 152篇 |
2016年 | 169篇 |
2015年 | 208篇 |
2014年 | 286篇 |
2013年 | 356篇 |
2012年 | 538篇 |
2011年 | 513篇 |
2010年 | 348篇 |
2009年 | 291篇 |
2008年 | 477篇 |
2007年 | 469篇 |
2006年 | 403篇 |
2005年 | 389篇 |
2004年 | 322篇 |
2003年 | 313篇 |
2002年 | 277篇 |
2001年 | 61篇 |
2000年 | 45篇 |
1999年 | 71篇 |
1998年 | 75篇 |
1997年 | 67篇 |
1996年 | 73篇 |
1995年 | 69篇 |
1994年 | 63篇 |
1993年 | 62篇 |
1992年 | 39篇 |
1991年 | 37篇 |
1990年 | 36篇 |
1989年 | 52篇 |
1988年 | 63篇 |
1987年 | 46篇 |
1986年 | 39篇 |
1985年 | 32篇 |
1984年 | 36篇 |
1983年 | 33篇 |
1982年 | 40篇 |
1981年 | 38篇 |
1980年 | 25篇 |
1979年 | 21篇 |
1978年 | 20篇 |
1976年 | 15篇 |
1975年 | 19篇 |
1974年 | 18篇 |
1972年 | 13篇 |
排序方式: 共有7579条查询结果,搜索用时 31 毫秒
1.
2.
3.
Pascal Delsart Camille Delahaye Patrick Devos Olivia Domanski Richard Azzaoui Jonathan Sobocinski Francis Juthier Andre Vincentelli Natacha Rousse Agnes Mugnier Jerome Soquet Valentin Loobuyck Mohamed Koussa Thomas Modine Bruno Jegou Antoine Bical Ilir Hysi Olivier Fabre Franois Pontana Regis Matran Claire MounierVehier David Montaigne 《Clinical cardiology》2021,44(2):252
BackgroundAlthough recommendations encourage daily moderate activities in post aortic dissection, very little data exists regarding cardiopulmonary exercise testing (CPET) to personalize those patient''s physical rehabilitation and assess their cardiovascular prognosis.DesignWe aimed at testing the prognostic insight of CPET regarding aortic and cardiovascular events by exploring a prospective cohort of patients followed‐up after acute aortic dissection.MethodsPatients referred to our department after an acute (type A or B) aortic dissection were prospectively included in a cohort between September 2012 and October 2017. CPET was performed once optimal blood pressure control was obtained. Clinical follow‐up was done after CPET for new aortic event and major cardio‐vascular events (MCE) not directly related to the aorta.ResultsAmong the 165 patients who underwent CPET, no adverse event was observed during exercise testing. Peak oxygen pulse was 1.46(1.22‐1.84) mlO2/beat, that is, 97 (83–113) % of its predicted value, suggesting cardiac exercise limitation in a population under beta blockers (92% of the population). During a follow‐up of 39(20‐51) months from CPET, 42 aortic event recurrences and 22 MCE not related to aorta occurred. Low peak oxygen pulse (<85% of predicted value) was independently predictive of aortic event recurrence, while low peak oxygen uptake (<70% of predicted value) was an independent predictor of MCE occurrence.ConclusionCPET is safe in postaortic dissection patients should be used to not only to personalize exercise rehabilitation, but also to identify those patients with the highest risk for new aortic events and MCE not directly related to aorta. 相似文献
4.
Priscila Rios Bomfim Chaves Alexandre Melo Karam Andre Wilson Machado 《The Angle orthodontist》2021,91(1):54
ObjectiveTo evaluate the influence of a midline diastema on dentofacial esthetic perceptions of orthodontists, restorative dental specialists or prosthodontists, and laypersons in a frontal facial evaluation performed by means of video.Materials and MethodsTwo individuals aged between 20 and 25 years, one of each gender, with presence of a midline diastema were selected. An acrylic resin mockup was made of the maxillary anterior region, simulating ideal conditions of smile esthetics. Four standardized frontal view videos of the complete face were filmed of each individual in the following situations: with the ideal smile (unchanged mockup) and with the presence of midline diastemas of 0.5, 1.0, and 1.5 mm created by the mockup. In all videos, the patient said a certain sentence and, at the end, simulated a posed smile. Dentofacial esthetic perceptions of all four videos of each individual were evaluated by 51 orthodontists, 51 restorative dental specialists or prosthodontists, and 51 laypersons by means of visual analog scales. Data were evaluated using analysis of variance and Tukey post hoc test, with the level of significance set at 5%.ResultsThe most attractive videos for all groups of examiners were those without diastema and with a diastema of 0.5 mm, for both the woman and the man. For a diastema of 1 mm or 1.5 mm, the dentofacial characteristics were considered unesthetic.ConclusionsDiastemas equal to or greater than 1 mm negatively influence dentofacial esthetics in a frontal facial evaluation performed by means of video. 相似文献
5.
The merits of surgical treatment of fractures of the mandibular condyle versus non-surgical management remains highly controversial, despite a large volume of literature dedicated to this topic. One reason the controversy remains, is because most of the outcomes in the literature are not directly comparable. The disparate range of condylar fracture classifications used is one of the reasons that studies are not comparable. We sought to review classification systems for condylar fractures used in the recent scientific literature.Review of the literature from 2016 to 2019, looking for papers relating to fractures of the mandibular condyle. Papers identified were assessed for type of study, focus of study, classification system used.88 studies were identified, including prospective and retrospective cohort studies, randomised and non-randomised prospective studies, randomised controlled trials and case series. More studies focussed on epidemiological factors than surgical access, fixation or outcomes. 31 used no classification system, whilst 17 used unique classification systems and 40 used previously referenced classification systems.Classification systems are used to help separate clinical problems into distinguishable groups, where there is a difference in management or outcome depending on the distinguishing features.There is currently a wide diversity of classification systems used for condyle fractures, and as a result, comparisons of surgical access, fixation and outcomes are difficult to make. Having a single classification system across the published literature would allow easier comparison and the classification proposed by the AO group is recommended for future use. 相似文献
6.
Thierry Andre Mayur Amonkar Josephine M Norquist Kai-Keen Shiu Tae Won Kim Benny Vittrup Jensen Lars Henrik Jensen Cornelis J A Punt Denis Smith Rocio Garcia-Carbonero Isabel Sevilla Christelle De La Fouchardiere Fernando Rivera Elena Elez Luis A Diaz Takayuki Yoshino Eric Van Cutsem Ping Yang Dung T Le 《The lancet oncology》2021,22(5):665-677
7.
Hope S. Rugo Jens Huober Jos A. GarcíaSenz Norikazu Masuda Joo Hyuk Sohn Valerie A.M. Andre Susana Barriga Joanne Cox Matthew Goetz 《The oncologist》2021,26(1):e53-e65
BackgroundAbemaciclib demonstrated efficacy in hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. Here we provide a comprehensive summary of the most common adverse events (AEs), their management, and whether AEs or dose reductions influenced progression‐free survival (PFS), in the MONARCH 2 and 3 trials.Materials and MethodsIncidence of the most clinically relevant AEs, management, and outcomes were summarized. Time‐dependent covariate analyses examined the impact of dose reductions on PFS. PFS was estimated for patients with and without early onset of diarrhea or neutropenia.ResultsThe most frequently reported AE was diarrhea, with clinically significant diarrhea (grade ≥2) reported for 42.8% of patients taking abemaciclib. Median time to onset was 1 week, and duration ranged from 6 to 12 days, depending on grade and study. Diarrhea was adequately managed by antidiarrheal medication (72.8%), dose omissions (17.3%), and reductions (16.7%). The highest rates of grade ≥2 diarrhea were observed in the first cycles and decreased in subsequent cycles. Neutropenia (grade ≥3) occurred in 25.4% of abemaciclib‐treated patients. Neutropenia resolved with dose omissions (16.8%) and/or dose reductions (11.2%). Incidence of febrile neutropenia (0.7%) or other relevant grade ≥3 hematological events (<9%) was low. Venous thromboembolic events (5.3%) were primarily treated with anticoagulants. Interstitial lung disease/pneumonitis (3.4%) was treated with corticosteroids and/or antibiotics. PFS benefit of abemaciclib was not impacted by dose reductions or early onset of toxicities.ConclusionAbemaciclib was generally well tolerated. The most common AEs were effectively managed by supportive medications, and/or dose adjustments, with no detriment to PFS.Implications for PracticeTreatment with abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitors is generally well tolerated in patients with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer. In MONARCH 2 and MONARCH 3, any‐grade diarrhea and grade ≥3 neutropenia were effectively managed with supportive medication and/or dose adjustment. Venous thromboembolic events were treated with anticoagulants and did not often require treatment discontinuation. Interstitial lung disease/pneumonitis was infrequent and treated with corticosteroids and/or antibiotics. Clinicians should be aware of and implement management strategies, including dose adjustments according to local labels, for commonly occurring and serious adverse events to ensure continued treatment and optimize clinical benefit/risk ratio. 相似文献
8.
9.
Annekathrin Haberland Oxana Krylova Heike Nikolenko Peter Gttel Andre Dallmann Johannes Müller Hardy Weisshoff 《Viruses》2021,13(5)
COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease. When now repurposing a drug, namely an aptamer that interacts with SARS-CoV-2 proteins for COVID-19 treatment (BC 007), which is, however, a neutralizer of pathogenic autoantibodies in its original indication, the possibility of also binding and neutralizing anti-SARS-CoV-2 antibodies must be considered. Here, the highly specific virus-neutralizing antibodies have to be distinguished from the ones that also show cross-reactivity to tissues. The last-mentioned could be the origin of the widely reported SARS-CoV-2-induced autoimmunity, which should also become a target of therapy. We, therefore, used enzyme-linked immunosorbent assay (ELISA) technology to assess the binding of well-characterized publicly accessible anti-SARS-CoV-2 antibodies (CV07-209 and CV07-270) with BC 007. Nuclear magnetic resonance spectroscopy, isothermal calorimetric titration, and circular dichroism spectroscopy were additionally used to test the binding of BC 007 to DNA-binding sequence segments of these antibodies. BC 007 did not bind to the highly specific neutralizing anti-SARS-CoV-2 antibody but did bind to the less specific one. This, however, was a lot less compared to an autoantibody of its original indication (14.2%, range 11.0–21.5%). It was also interesting to see that the less-specific anti-SARS-CoV-2 antibody also showed a high background signal in the ELISA (binding on NeutrAvidin-coated or activated but noncoated plastic plate). These initial experiments suggest that the risk of binding and neutralizing highly specific anti-SARS CoV-2 antibodies by BC 007 should be low. 相似文献